News Releases

November 22, 2021
Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618
Interim data from Phase 2 SynPheny-1 trial featured in late-breaking oral presentation during 14th International Congress of Inborn Errors of Metabolism Meeting Data demonstrate ability of SYNB1618 to consume phenylalanine from the GI tract Synlogic also presents two posters with additional data on...
November 10, 2021
Synlogic Reports Third Quarter Financial Results and Provides Business Update
- Interim analysis of Phase 2 SynPheny-1 study demonstrated proof of concept in phenylketonuria. Program to advance to Phase 3 development - - Research milestone in inflammatory bowel disease collaboration with Roche achieved - - $150.1 million in cash, cash equivalents and short-term investments...
November 10, 2021
Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting
CAMBRIDGE, Mass. , Nov. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data from the company's clinical development program for phenylketonuria (PKU) during...
November 9, 2021
Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
Synlogic and Ginkgo collaboration generates clinical candidate SYNB1353 using Synlogic's proprietary Synthetic Biotic platform and Ginkgo Codebase SYNB1353 is the first investigational medicine developed from Ginkgo's platform to advance to IND-enabling studies Synlogic to present preclinical data...
November 2, 2021
Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
CAMBRIDGE, Mass. , Nov. 2, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2021 financial results before the market opens on Wednesday,...
October 28, 2021
Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria
CAMBRIDGE, Mass. , Oct. 28, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced a publication in Nature Communications documenting the engineering of a more potent phenylalanine...
October 15, 2021
Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
- Real-world evidence dataset demonstrates relationship between higher urinary oxalate levels and increased incidence of chronic kidney disease - - Additional clinical data presented on SYNB8802 in a healthy volunteer model of diet-induced hyperoxaluria - - Phase 1b study of SYNB8802 in enteric...
October 12, 2021
Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform
CAMBRIDGE, Mass. , Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic products designed using the...
September 27, 2021
Synlogic Appoints Molly Harper as Chief Business Officer
CAMBRIDGE, Mass. , Sept. 27, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms....
September 22, 2021
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering...
September 22, 2021
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....
September 20, 2021
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
-- SYNB1618 demonstrated proof of concept with meaningful reduction of plasma phenylalanine (Phe) levels in an interim analysis of the Phase 2 SynPheny-1 Study -- -- SYNB1934, an optimized strain of SYNB1618, demonstrated two-fold increase in biomarkers of Phe metabolism compared to SYNB1618 -- --...
Displaying 1 - 12 of 162